Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05153954
Other study ID # REG-046-2021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 31, 2021
Est. completion date August 31, 2024

Study information

Verified date January 2023
Source Zealand University Hospital
Contact Carolin Oppermann, MD
Phone 004952115957
Email caopp@regionsjaelland.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Fluorescence angiography with indocyanine green (ICG-FA) has gained increased popularity in colorectal surgery to check perfusion to the newly-formed anastomotic area and decrease the rate of postoperative anastomotic leakage. While qualitative ICG assessment has the advantage to be used instantly during the operative procedure, it does bear drawbacks (subjective assessment, dependent on factors like camera distance, ICG dose and white-light contamination). The alternative is quantitative ICG assessment, which is performed by evaluating the time-intensity curve of the ICG-FA with an external analyzing software. The procedure is showing promising results, but the methodology is still reported very heterogeneously. This study is a multi-center, prospective, standardized, surgeon-blinded observational trial. The key aspect of this study is the non-interventional design with blinding of both the qualitative and quantitative results from the ICG perfusion measurement, providing no chance of influencing the course of the operation. Assessment of perfusion will be performed postoperatively blinded to the outcome. Assessment of the pre-anastomotic area is intraoperatively performed by an image analysis software that then calculates a perfusion score based on an algorithm integrating relevant perfusion metrics. The primary outcome is the combined rate of early and late anastomotic complications within 90 days postoperatively.


Recruitment information / eligibility

Status Recruiting
Enrollment 115
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older - Capable of giving informed consent - ASA Classification: status I-III - Planned for PME or TME with minimally invasive approach and primary anastomosis - Strong suspicion of or biopsy-verified sigmoid or rectal cancer Stage I-IV cancer Exclusion Criteria: - Known allergy to ICG or iodine - Emergency procedure - Pregnancy or if the patient is currently nursing - Surgeons decide to do unblinded quantitative or qualitative ICG-FA

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Quantitative Indocyanine Green Fluorescence Angiography
Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis

Locations

Country Name City State
Denmark Department of Surgery, Herlev Hospital Herlev
Denmark Department of Surgery, Zealand University Hospital Køge Region Zealand

Sponsors (2)

Lead Sponsor Collaborator
Zealand University Hospital Perfusion Tech Aps

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative anastomotic complications combined rate of all anastomotic complications 3 months
Secondary Number of participants with complications according to Clavien-Dindo Classification 90 days
Secondary Number of participants with anastomotic leakage rate, severity (grade A-C) 90 days
Secondary Number of participants with postoperative bleeding 10 days
Secondary Number of participants with postoperative paralytic ileus obstipation and intolerance of oral intake due to nonmechanical factors that disrupt the normal coordinated propulsive motor activity of the gastrointestinal tract following abdominal surgery 90 days
Secondary Number of participants with wound dehiscence surgical complication in which a wound ruptures along a surgical incision 1 month
Secondary Comprehensive complications index 90 days
Secondary Duration of surgery 1 day
Secondary Reoperation rate 1 month
Secondary Hospital readmission Number of patients had have to be readmitted to the hospital due to postoperative complications 1 month
Secondary Length of hospital stay 1 month
Secondary QT interval variability Continuous ECG-monitoring intraoperatively and postoperatively 2 days
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A